能谱CT及MRI功能成像评估头颈部鳞状细胞癌患者侵袭性及新辅助化疗效果的研究

注册号:

Registration number:

ChiCTR2300073227 

最近更新日期:

Date of Last Refreshed on:

2023-08-31 12:01:49 

注册时间:

Date of Registration:

2023-07-04 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

能谱CT及MRI功能成像评估头颈部鳞状细胞癌患者侵袭性及新辅助化疗效果的研究

Public title:

Evaluation of aggressiveness and neoadjuvant chemotherapy in patients with squamous cell carcinoma of head and neck by energy spectrum CT and MRI functional imaging

注册题目简写:

English Acronym:

研究课题的正式科学名称:

能谱CT及MRI功能成像评估头颈部鳞状细胞癌患者侵袭性及新辅助化疗效果的研究

Scientific title:

Evaluation of aggressiveness and neoadjuvant chemotherapy in patients with squamous cell carcinoma of head and neck by energy spectrum CT and MRI functional imaging

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨玲洁 

研究负责人:

段小慧 

Applicant:

Lingjie Yang 

Study leader:

Xiaohui Duan 

申请注册联系人电话:

Applicant telephone:

+86 159 8903 6151

研究负责人电话:

Study leader's
telephone:

+86 135 1276 2365

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yanglj53@mail2.sysu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

duanxh5@mail.sysu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市沿江西路107号

研究负责人通讯地址:

广东省广州市沿江西路107号

Applicant address:

107 Yanjiang Road West, Guangzhou, Guangdong

Study leader's address:

107 Yanjiang Road West, Guangzhou, Guangdong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中山大学孙逸仙纪念医院

Applicant's institution:

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

研究负责人所在单位:

中山大学孙逸仙纪念医院

Affiliation of the Leader:

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SYSEC-KY-KS-2021-317

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学孙逸仙纪念医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-12-10 00:00:00

伦理委员会联系人:

林双秀

Contact Name of the ethic committee:

Shuangxiu Lin

伦理委员会联系地址:

广东省广州市沿江西路107号

Contact Address of the ethic committee:

107 Yanjiang Road West, Guangzhou, Guangdong

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8133 2587

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中山大学孙逸仙纪念医院

Primary sponsor:

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

研究实施负责(组长)单位地址:

广东省广州市沿江西路107号

Primary sponsor's address:

107 Yanjiang Road West, Guangzhou, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学孙逸仙纪念医院

具体地址:

广东省广州市沿江西路107号

Institution
hospital:

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Address:

107 Yanjiang Road West, Guangzhou, Guangdong

经费或物资来源:

立项经费

Source(s) of funding:

Project funding

研究疾病:

头颈部鳞状细胞癌  

Target disease:

squamous cell carcinoma of head and neck

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

探索定量能谱CT及MRI功能成像(DCE、DKI)参数在HNSCC的HNSCC的侵袭性及新辅助化疗效果的潜在作用。  

Objectives of Study:

To explore the potential role of quantitative energy spectrum CT and MRI functional imaging (DCE, DKI) parameters in HNSCC invasiveness and neoadjuvant chemotherapy effect.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.既往有化疗和/或放疗史; 2.未手术切除; 3.手术切除与影像检查间隔>2周; 4.明显伪影; 5.CT及MRI扫描禁忌症。

Exclusion criteria:

1. Previous history of chemotherapy and/or radiotherapy; 2. No surgical resection; 3. The interval between surgical resection and imaging examination > 2 weeks; 4. Obvious artifacts; 5. Contraindications to CT and MRI scanning.

研究实施时间:

Study execute time:

From 2021-12-10 00:00:00 To 2024-05-16 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-12-10 00:00:00 To 2024-05-16 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

病理确诊为头颈鳞癌患者

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

The pathological diagnosis was head and neck squamous cell carcinoma.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

灵敏度;特异度;准确度;阳性预测值;阴性预测值

Index test:

sensitivity; specificity; accuracy; positive predictive value; negative predictive value

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

病理确诊为头颈鳞癌的患者

例数:

Sample size:

274

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patiens pathologically diagnosed with head and neck squamous cell carcinoma.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

None

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

中山大学孙逸仙纪念医院 

单位级别:

三级甲等 

Institution
hospital:

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

双能CT和MR功能序列参数

指标类型:

主要指标

Outcome:

Dual-energy CT and MR function sequence parameters

Type:

Primary indicator

测量时间点:

获得磁共振功能序列后

测量方法:

绘制感兴趣区

Measure time point of outcome:

after obtaining the functional MRI sequence

Measure method:

delineate the ROI

指标中文名:

准确度

指标类型:

主要指标

Outcome:

Accuracy

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

灵敏度

指标类型:

主要指标

Outcome:

Sensitivity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

特异度

指标类型:

主要指标

Outcome:

Specificity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阳性预测值

指标类型:

主要指标

Outcome:

Positive predicative value

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴性预测值

指标类型:

主要指标

Outcome:

Negative predictive value

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

肿瘤

组织:

Sample Name:

tumors

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

无(本研究根据术后病理进行分组)。

Randomization Procedure (please state who generates the random number sequence and by what method):

none (This study was grouped according to postoperative pathology)..

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2023.11.11 中山大学孙逸仙纪念医院保存。临床试验公共管理平台 IPD(http://www.medresman.org.cn)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2023.11.11 Preserved at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. ResMan IPD (http://www.medresman.org.cn).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究扫描数据首先传至医院PACS系统保存,同时用硬盘进行数据备份,由科研秘书专人保管。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data of this study were first transferred to the hospital PACS system for storage, while the data were backed up with a hard disk and kept by a dedicated research secretary.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-07-04 16:43:04